BeOne Medicines Ltd ADR's income statement, balance sheet and cash flow statement as filed with the SEC (10-K and 10-Q), with the latest fiscal years and quarters. In its latest fiscal year (Dec 31, 2025 · FY), BeOne Medicines Ltd ADR reported revenue of $5.3B (+40.2% year on year) and net income of $286.9M (+144.5% year on year).
| Line item | Dec 31, 2025 · FY | Dec 31, 2024 · FY | Dec 31, 2023 · FY | Dec 31, 2022 · FY |
|---|---|---|---|---|
| Total revenues | $5.3B | $3.8B | $2.5B | $1.4B |
| Cost of sales - product | $668.5M | $594.1M | $379.9M | $286.5M |
| Gross profit | $4.7B | $3.2B | $2.1B | — |
| Research and development | $2.1B | $2.0B | $1.8B | $1.6B |
| Selling, general and administrative | $2.1B | $1.8B | $1.5B | $1.3B |
| Total operating expenses | $4.2B | $3.8B | $3.3B | $3.2B |
| Income (loss) from operations | $447.1M | ($568.2M) | ($1.2B) | ($1.8B) |
| Interest income | $70.5M | — | — | — |
| Interest expense | ($58.2M) | — | — | — |
| Other (expense) income, net | ($42.6M) | ($12.6M) | $307.9M | ($223.9M) |
| Income (loss) before income taxes | $416.9M | ($533.0M) | — | — |
| Income tax expense | $129.9M | $111.8M | $55.9M | $42.8M |
| Net income (loss) | $286.9M | ($644.8M) | ($881.7M) | ($2.0B) |
| Basic (in dollars per share) | $0.20 | -$0.47 | -$0.65 | -$1.49 |
| Diluted (in dollars per share) | $0.19 | -$0.47 | -$0.65 | -$1.49 |
| Weighted-average shares outstanding—basic (in shares) | 1.4B | 1.4B | 1.4B | 1.3B |
| Weighted-average shares outstanding— diluted (in shares) | 1.5B | 1.4B | 1.4B | 1.3B |
| Basic (in dollars per share) | $2.63 | -$6.12 | -$8.45 | -$19.43 |
| Diluted (in dollars per share) | $2.53 | -$6.12 | -$8.45 | -$19.43 |
| Weighted-average ADSs outstanding, basic (in shares) | 109.1M | 105.3M | 104.4M | 103.1M |
| Weighted-average ADSs outstanding, diluted (in shares) | 113.4M | 105.3M | 104.4M | 103.1M |
| Line item | Jun 30, 2026 · Q2 | Mar 31, 2026 · Q1 | Sep 30, 2025 · Q3 | Jun 30, 2025 · Q2 |
|---|---|---|---|---|
| Total revenues | $1.7B | $1.5B | $1.4B | $1.3B |
| Cost of sales - product | $174.5M | $167.2M | $196.5M | $164.6M |
| Gross profit | $1.5B | $1.3B | $1.2B | $1.2B |
| Research and development | $612.3M | $541.2M | $523.7M | $524.9M |
| Selling, general and administrative | $593.2M | $555.1M | $529.0M | $537.9M |
| Total operating expenses | $1.2B | $1.1B | $1.1B | $1.1B |
| Income from operations | $325.0M | $249.9M | $163.1M | $87.9M |
| Interest income | $27.9M | $27.7M | — | — |
| Interest expense | ($39.7M) | ($32.9M) | — | — |
| Other (expense) income, net | ($749.0K) | $14.5M | ($19.0M) | $8.2M |
| Income before income taxes | $312.5M | $259.2M | $147.2M | $99.5M |
| Income tax expense | $75.5M | $31.9M | $22.3M | $5.2M |
| Net income | $237.0M | $227.4M | $124.8M | $94.3M |
| Basic (in dollars per share) | $0.16 | $0.16 | $0.09 | $0.07 |
| Diluted (in dollars per share) | $0.16 | $0.15 | $0.08 | $0.06 |
| Weighted-average shares outstanding—basic (in shares) | 1.5B | 1.4B | 1.4B | 1.4B |
| Weighted-average shares outstanding— diluted (in shares) | 1.5B | 1.5B | 1.5B | 1.5B |
| Basic (in dollars per share) | $2.12 | $2.05 | $1.13 | $0.87 |
| Diluted (in dollars per share) | $2.05 | $1.96 | $1.09 | $0.84 |
| Weighted-average ADSs outstanding - basic (in shares) | 111.6M | 111.0M | 110.2M | 108.3M |
| Weighted-average ADSs outstanding - diluted (in shares) | 115.8M | 115.8M | 114.5M | 112.6M |
| Line item | Dec 31, 2025 · FY | Dec 31, 2024 · FY | Dec 31, 2023 · FY | Dec 31, 2022 · FY |
|---|---|---|---|---|
| Cash and cash equivalents | $4.5B | $2.6B | $3.2B | $3.9B |
| Accounts receivable, net | $865.1M | $676.3M | $358.0M | $173.2M |
| Inventories, net | $608.2M | $495.0M | $416.1M | $282.3M |
| Prepaid expenses and other current assets | $212.8M | $192.9M | $243.4M | $216.6M |
| Total current assets | $6.2B | $4.0B | $4.2B | $5.2B |
| Property, plant and equipment, net | $1.6B | $1.6B | $1.3B | $845.9M |
| Operating lease right-of-use assets | $148.2M | $139.3M | $95.2M | $110.0M |
| Intangible assets, net | $62.7M | $51.1M | $57.1M | $40.6M |
| Other non-current assets | $102.4M | $160.5M | $125.4M | $170.4M |
| Total non-current assets | $2.0B | $1.9B | $1.6B | $1.2B |
| Total assets | $8.2B | $5.9B | $5.8B | $6.4B |
| Accounts payable | $479.0M | $405.0M | $315.1M | $294.8M |
| Accrued expenses and other payables | $1.1B | $803.7M | $693.7M | $467.4M |
| Tax payable | $41.6M | $25.9M | $23.0M | $25.2M |
| Operating lease liabilities, current portion | $20.7M | $17.6M | $21.9M | $24.0M |
| Research and development cost share liability, current portion | $64.3M | $111.2M | $68.0M | $114.3M |
| Sale of future royalty liability, current portion | $56.7M | — | — | — |
| Short-term debt | $57.3M | $851.5M | $688.4M | $329.0M |
| Total current liabilities | $1.8B | $2.2B | $1.8B | $1.5B |
| Long-term debt | $961.9M | $166.5M | $197.6M | $209.1M |
| Sale of future royalty liability, non-current portion | $850.2M | — | — | — |
| Operating lease liabilities, non-current portion | $52.9M | $44.3M | $22.3M | $34.5M |
| Deferred tax liabilities | $53.2M | $42.0M | $16.5M | $16.0M |
| Research and development cost share liability, non-current portion | $0 | $54.3M | $170.7M | $179.6M |
| Other long-term liabilities | $80.2M | $66.7M | $50.5M | $46.1M |
| Total non-current liabilities | $2.0B | $373.8M | $457.8M | $527.4M |
| Total liabilities | $3.8B | $2.6B | $2.3B | $2.0B |
| Ordinary shares, $0.0001 par value per share; 1,540,975,898 and 1,387,367,704 shares issued and 1,441,075,618 and 1,387,367,704 shares outstanding as of December 31, 2025 and 2024, respectively | $144000.00 | $138000.00 | $135000.00 | $135000.00 |
| Additional paid-in capital | $12.8B | $12.1B | $11.6B | $11.5B |
| Accumulated other comprehensive loss | ($78.2M) | ($149.0M) | ($99.4M) | ($77.4M) |
| Accumulated deficit | ($8.3B) | ($8.6B) | ($8.0B) | ($7.1B) |
| Total shareholders’ equity | $4.4B | $3.3B | $3.5B | $4.4B |
| Total liabilities and shareholders’ equity | $8.2B | $5.9B | $5.8B | $6.4B |
| Line item | Jun 30, 2026 | Mar 31, 2026 | Sep 30, 2025 | Jun 30, 2025 |
|---|---|---|---|---|
| Cash and cash equivalents | $5.1B | $4.8B | $4.0B | $2.8B |
| Accounts receivable, net | $1.1B | $938.0M | $863.3M | $770.8M |
| Inventories, net | $732.6M | $681.6M | $531.7M | $502.9M |
| Prepaid expenses and other current assets | $329.0M | $190.0M | $232.6M | $280.5M |
| Total current assets | $7.2B | $6.6B | $5.7B | $4.3B |
| Property, plant and equipment, net | $1.6B | $1.6B | $1.6B | $1.6B |
| Operating lease right-of-use assets | $146.0M | $145.5M | $140.2M | $145.8M |
| Intangible assets, net | $61.0M | $61.7M | $63.6M | $64.9M |
| Other non-current assets | $109.6M | $104.2M | $136.2M | $161.7M |
| Total non-current assets | $2.0B | $2.0B | $2.0B | $2.0B |
| Total assets | $9.2B | $8.6B | $7.6B | $6.3B |
| Accounts payable | $470.3M | $423.5M | $383.7M | $360.8M |
| Accrued expenses and other payables | $1.3B | $1.1B | $1.0B | $908.9M |
| Tax payable | $76.3M | $63.5M | $11.2M | $5.5M |
| Operating lease liabilities, current portion | $22.0M | $20.6M | $15.7M | $17.3M |
| Research and development cost share liability, current portion | $6.2M | $35.7M | $90.6M | $109.0M |
| Sale of future royalty liability, current portion | $89.3M | $72.7M | $52.2M | — |
| Short-term debt | $190.9M | $116.1M | $813.3M | $808.4M |
| Total current liabilities | $2.1B | $1.8B | $2.4B | $2.2B |
| Long-term debt | $882.2M | $962.5M | $139.6M | $146.1M |
| Sale of future royalty liability, non-current portion | $817.0M | $831.7M | $832.8M | — |
| Operating lease liabilities, non-current portion | $48.2M | $49.7M | $51.4M | $53.9M |
| Deferred tax liabilities | $57.4M | $55.9M | $47.1M | $44.1M |
| Other long-term liabilities | $77.6M | $82.0M | $64.1M | $63.1M |
| Total non-current liabilities | $1.9B | $2.0B | $1.1B | $318.1M |
| Total liabilities | $4.0B | $3.8B | $3.5B | $2.5B |
| Ordinary shares, $0.0001 par value per share; 1,540,975,898 and 1,540,975,898 shares issued and 1,469,278,815 and 1,441,075,618 shares outstanding as of June 30, 2026 and December 31, 2025, respectively | $147000.00 | $144000.00 | $144000.00 | $143000.00 |
| Additional paid-in capital | $13.1B | $12.9B | $12.6B | $12.4B |
| Accumulated other comprehensive loss | ($25.4M) | ($53.5M) | ($101.3M) | ($113.7M) |
| Accumulated deficit | ($7.9B) | ($8.1B) | ($8.4B) | ($8.5B) |
| Total shareholders’ equity | $5.2B | $4.8B | $4.1B | $3.8B |
| Total liabilities and shareholders’ equity | $9.2B | $8.6B | $7.6B | $6.3B |
| Line item | Dec 31, 2025 · FY | Dec 31, 2024 · FY | Dec 31, 2023 · FY | Dec 31, 2022 · FY |
|---|---|---|---|---|
| Net income (loss) | $286.9M | ($644.8M) | — | — |
| Depreciation and amortization expense | $141.7M | $171.8M | $87.7M | $66.3M |
| Share-based compensation expense | $510.9M | $441.6M | $367.6M | $303.2M |
| Acquired in-process research and development | $691.0K | $60.0M | $46.8M | $68.7M |
| Amortization of research and development cost share liability | ($101.1M) | ($73.2M) | ($55.3M) | ($96.4M) |
| Impairment of equity investments | $75.6M | — | — | — |
| Loss on long-term investments | ($596.0K) | — | — | — |
| Non-cash interest expense | $14.9M | — | — | — |
| Deferred income tax expense | $9.5M | $26.0M | $689.0K | $2.1M |
| Gain on BMS termination settlement | $0 | $0 | ($362.9M) | — |
| Other items, net | ($3.0M) | $11.2M | ($6.0M) | $9.0M |
| Accounts receivable | ($165.0M) | ($329.4M) | ($188.3M) | $304.1M |
| Inventories | ($93.2M) | ($91.5M) | ($140.9M) | ($56.7M) |
| Other assets | $37.2M | $45.1M | $12.1M | ($3.3M) |
| Accounts payable | $79.8M | $121.5M | $21.5M | ($4.4M) |
| Accrued expenses and other payables | $311.8M | $111.4M | $180.1M | $45.6M |
| Deferred revenue | $1.3M | $633.0K | ($255.6M) | ($151.8M) |
| Other liabilities | $19.0M | ($14.8M) | $587.0K | ($1.2M) |
| Net cash provided by (used in) operating activities | $1.1B | ($140.6M) | ($1.2B) | ($1.5B) |
| Purchases of property and equipment | ($185.8M) | ($492.7M) | ($561.9M) | ($325.4M) |
| Purchase of in-process research and development | ($60.7M) | ($31.8M) | ($15.0M) | ($143.7M) |
| Purchase of intangible assets | ($20.0M) | ($4.7M) | ($19.4M) | $0 |
| Purchase of long-term investments | ($11.8M) | ($19.0M) | ($14.9M) | ($15.9M) |
| Proceeds from sale or maturity of short-term investments | $3.4M | $2.7M | $673.2M | $1.6B |
| Other investing activities | ($1.2M) | ($2.9M) | — | $0 |
| Net cash (used in) provided by investing activities | ($276.2M) | ($548.4M) | $60.0M | $1.1B |
| Proceeds from sale of future royalties | $911.0M | — | — | — |
| Proceeds from long-term loan | $850.6M | $9.1M | $22.5M | $37.4M |
| Repayment of long-term loan | ($35.7M) | ($28.0M) | ($13.7M) | $0 |
| Proceeds from short-term loans | $233.7M | $868.3M | $661.5M | $313.8M |
| Repayment of short-term loans | ($1.0B) | ($704.2M) | ($309.6M) | ($417.1M) |
| Payments of debt issuance costs | ($23.4M) | — | — | — |
| Payments of withholding taxes from share-based awards | ($24.2M) | — | — | — |
| Proceeds from option exercises and employee share purchase plan | 196.3M | 45.4M | 55.7M | 47.0M |
| Repayment of sale of future royalties liability | ($4.0M) | — | — | — |
| Other financing activities | $0 | $3.0M | — | — |
| Net cash provided by financing activities | $1.1B | $193.4M | $416.5M | ($19.0M) |
| Effect of foreign exchange rate changes, net | $60.0M | ($51.7M) | ($8.1M) | ($69.4M) |
| Net increase (decrease) in cash, cash equivalents, and restricted cash | $2.0B | ($547.2M) | ($689.1M) | ($507.9M) |
| Cash, cash equivalents, and restricted cash, beginning of year | $2.6B | $3.2B | $3.9B | $4.4B |
| Cash, cash equivalents, and restricted cash, end of year | $4.6B | $2.6B | $3.2B | $3.9B |
| Cash and cash equivalents | $4.5B | $2.6B | $3.2B | $3.9B |
| Short-term restricted cash | $41.3M | $9.3M | $11.5M | $196.0K |
| Long-term restricted cash | $20.8M | $2.0M | $2.7M | $5.3M |
| Interest paid | $52.5M | $51.2M | $19.8M | $25.2M |
| Line item | Jun 30, 2026 · YTD | Mar 31, 2026 · Q1 | Sep 30, 2025 · YTD | Jun 30, 2025 · YTD |
|---|---|---|---|---|
| Net income | $464.4M | $227.4M | $220.4M | $95.6M |
| Depreciation and amortization expense | $81.7M | $41.1M | $105.7M | $68.4M |
| Share-based compensation expenses | $260.8M | $123.4M | $387.1M | $246.3M |
| Acquired in-process research and development | $20.5M | — | $691.0K | $500.0K |
| Amortization of research and development cost share liability | ($58.2M) | ($28.6M) | ($74.8M) | ($45.6M) |
| Other items, net | $14.4M | $6.2M | $9.6M | $15.1M |
| Accounts receivable | ($192.9M) | ($75.3M) | ($167.3M) | ($73.4M) |
| Inventories | ($119.0M) | ($71.8M) | ($22.7M) | $6.2M |
| Other assets | $3.9M | $15.3M | $55.2M | ($45.3M) |
| Accounts payable | ($4.7M) | ($42.2M) | ($7.4M) | ($35.9M) |
| Accrued expenses and other payables | $195.6M | ($16.8M) | $165.9M | $75.6M |
| Other liabilities | ($2.4M) | $1.7M | $3.5M | $64.0K |
| Net cash provided by operating activities | $664.2M | $201.3M | $710.2M | $307.7M |
| Purchases of property, plant and equipment | ($68.3M) | ($40.8M) | ($148.3M) | ($100.2M) |
| Purchase of intangible assets | $0 | — | ($20.0M) | ($20.0M) |
| Proceeds from sale or maturity of investments | $5.9M | $27.0K | $1.8M | $1.8M |
| Purchase of in-process research and development | ($20.5M) | $0 | ($60.7M) | ($60.0M) |
| Other investing activities | ($12.0M) | ($4.7M) | ($10.6M) | ($10.1M) |
| Net cash used in investing activities | ($94.9M) | ($45.5M) | ($237.8M) | ($188.5M) |
| Repayment of long-term loan | ($24.7M) | ($7.6M) | ($21.1M) | ($16.8M) |
| Proceeds from short-term loans | $58.2M | $58.2M | $221.5M | $221.5M |
| Repayment of short-term loans | $0 | $0 | ($275.8M) | ($275.8M) |
| Repayment of sale of future royalties liability | ($2.6M) | ($2.6M) | — | — |
| Payments of withholding taxes from share-based awards | $0 | — | ($24.2M) | ($24.2M) |
| Proceeds from option exercises and employee share purchase plan | 34.9M | 23.9M | 177.0M | 96.5M |
| Other financing activities | ($3.3M) | ($3.2M) | $0 | $0 |
| Net cash provided by financing activities | $62.6M | $68.6M | $962.5M | $1.2M |
| Effect of foreign exchange rate changes, net | $39.2M | $19.3M | $36.9M | $27.0M |
| Net increase in cash, cash equivalents, and restricted cash | $671.0M | $243.8M | $1.5B | $147.3M |
| Cash, cash equivalents, and restricted cash at beginning of period | $4.6B | $4.6B | $2.6B | $2.6B |
| Cash, cash equivalents, and restricted cash at end of period | $5.3B | $4.9B | $4.1B | $2.8B |
| Cash and cash equivalents | $5.1B | $4.8B | $4.0B | $2.8B |
| Short-term restricted cash | $161.0M | $40.8M | $53.0M | $15.8M |
| Long-term restricted cash | $21.6M | $20.9M | $20.7M | $14.2M |
| Income taxes paid | $67.9M | ($2.7M) | $80.0M | $77.0M |
| Interest expense paid | $26.3M | $12.8M | $36.1M | $24.0M |
| Capital expenditures included in accounts payable and accrued expenses | $49.1M | $43.2M | $52.1M | $57.9M |
| ROU assets obtained in exchange for new operating lease liabilities | $14.8M | $9.3M | $19.1M | $18.1M |
BeOne Medicines Ltd ADR score and earnings-call analysis · All covered companies
Figures as reported in SEC filings. General information, not investment advice.